Publication Name	World Journal of Nephrology
Manuscript ID	115933
Country	Colombia

Category	Urology & Nephrology
Manuscript Type	Observational Study
Article Title	Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial
Manuscript Source	Unsolicited Manuscript
All Author List	Rodrigo Daza Arnedo, Vicente Sánchez Polo, Jenniffer Benavides Garcia, Juan Felipe Gutiérrez, Enrique Ramos Clason, Daniel Domínguez, Giovany Mera Rebutti, Carlos Madrid Mancia, Rene Tabora López, Manuel Rocha Meza, Dany Tabora López, James J Muñoz Zambrano, Eduardo Lorca Herrera, Eliana Dina-Batlle, Michael Cieza Terrones, Thyago Proença de Moraes, Tomas Rodriguez Yánez, Washington Osorio, Alyi Arellano Cabeza and Jorge Rico-Fontalvo
Funding Agency and Grant Number
Corresponding Author	Jorge Rico-Fontalvo, Faculty of Medicine, Department of Nephrology, Simón Bolívar University of Barranquilla, 59th Street No. 59-65, Barranquilla 080002, Atlántico, Colombia. jorgericof@yahoo.com
Key Words	Finerenone; Chronic kidney disease; Type 2 diabetes; Diabetic nephropathy; Albuminuria; Hyperkalemia
Core Tip	In a real-world observational study of 347 Latin American patients with type 2 diabetes mellitus and chronic kidney disease finerenone demonstrated significant short-term benefits. After six months, treatment led to major reductions in the urinary albumin-creatinine ratio and blood pressure. This efficacy was achieved with very good tolerance; the estimated glomerular filtration rate remained stable, and serum potassium increases were minimal, highlighting a low risk of hyperkalemia. This study provides crucial real-world evidence supporting finerenone’s safety and effectiveness.
Citation	Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Zambrano JJM, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; In press

Received	2025-10-29 15:29
Peer-Review Started	2025-10-29 15:29
First Decision by Editorial Office Director	2025-12-04 09:03
Return for Revision	2025-12-04 09:03
Revised	2025-12-17 20:25
Publication Fee Transferred	2025-12-19 19:40
Second Decision by Editor	2026-01-28 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-01-28 12:32
Articles in Press	2026-01-28 12:32
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-6124 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com